Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis.
journal contributionposted on 03.08.2022, 13:26 authored by Mohamad A Kalot, Nedaa Husainat, Omar Abughanimeh, Osama Diab, Abdallah El Alayli, Sammy Tayiem, Bader Madoukh, Ahmad Bilal Dimassi, Aref Qureini, Barbara Ameer, Jeroen CJ Eikenboom, Nicolas Giraud, Sandra L Haberichter, Vicki Jacobs-Pratt, Barbara A Konkle, Simon McRae, Robert R Montgomery, James O'DonnellJames O'Donnell, Romina Brignardello-Petersen, Veronica H Flood, Nathan T Connell, Paula D James, Reem A Mustafa
Von Willebrand Disease (VWD) is associated with significant morbidity because of excessive bleeding. Early diagnosis and treatment is important to prevent and treat these symptoms. We systematically reviewed the accuracy of any VWF activity assay in the diagnosis and classification of patients for VWD. We searched Cochrane Central, MEDLINE, and EMBASE for eligible studies. Risk of bias was assessed using QUADAS-2 and certainty of evidence using the GRADE framework. We pooled estimates of sensitivity and specificity. The review included 77 studies that evaluated the use of newer tests of VWF platelet binding activity (VWF:GPIbR , VWF:GPIbM) and VWF:RCo for the diagnosis of VWD (13 studies), VWF propeptide to VWF:Ag ratio and desmopressin trial for the diagnosis of type 1C VWD (5 studies), VWF multimer analysis and VWF:CB/VWF:Ag ratio for the classification of type 2 VWD (11 studies), genetic testing and ristocetin-induced platelet aggregation to diagnose type 2B VWD (14 studies), genetic testing and FVIII:VWF binding to diagnose type 2N VWD (17 studies). Based on available diagnostic test accuracy, there appears to be comparable test accuracy results between newer tests of platelet binding activity of VWF function and VWF:RCo. The findings of these reviews support VWF multimer analysis or VWF:CB/VWF:Ag to diagnose type 2 VWD. The desmopressin trial test with 1- and 4-hour postinfusion blood work is the test of choice to confirm increased VWF clearance in patients with VWD suspected of type 1C. Additionally, genetic testing is most useful in diagnosing type 2B VWD and has a role in the diagnostic algorithm of suspected type 2N VWD.
American Society of Hematology (ASH)
CommentsThe original article is available at https://ashpublications.org/
Published CitationKalot MA. et al. Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis. Blood Adv. 2022;6(12):3735-3745.
Publication Date23 June 2022
- Irish Centre for Vascular Biology
- School of Pharmacy and Biomolecular Sciences
- Vascular Biology
PublisherAmerican Society of Hematology
- Published Version (Version of Record)